Loading...
Predilife S.A.
ALPRE.PA•EURONEXT
HealthcareMedical - Diagnostics & Research
$3.77
$0.02(0.51%)
Predilife S.A. (ALPRE.PA) Stock Overview
Explore Predilife S.A.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ALPRE.PAStats details for ALPRE.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALPRE.PAAnalyst Recommendations details for ALPRE.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.
CEO
Mr. Stephane Ragusa
Employees
19
Headquarters
39, Rue Camille Desmoulins, Villejuif
Founded
2018